INTANGIBLE ASSETS (Details Narrative) - USD ($)
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
9 Months Ended |
12 Months Ended |
Apr. 30, 2022 |
Sep. 30, 2021 |
Jan. 31, 2021 |
Dec. 31, 2020 |
Oct. 31, 2020 |
Mar. 31, 2020 |
Dec. 31, 2021 |
Mar. 31, 2021 |
Jun. 30, 2020 |
Mar. 31, 2020 |
Jun. 30, 2022 |
Sep. 30, 2022 |
Sep. 30, 2021 |
Dec. 31, 2021 |
Dec. 31, 2020 |
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of assets,value |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,425,000
|
$ 106,000
|
| Number of value, service |
|
|
|
|
|
|
$ 21,960
|
|
$ 23,300
|
$ 15,000
|
|
$ 51,750
|
$ 518,177
|
540,136
|
36,800
|
| Common stock issued for services, shares |
|
|
|
|
|
|
500
|
16,250
|
3,125
|
3,750
|
|
|
|
|
|
| Payments to acquire intangible assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
14,500
|
$ 34,300
|
| Website [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of value, service |
|
|
|
$ 22,500
|
|
$ 15,000
|
|
|
|
|
|
|
|
|
|
| Intangible assets remaining amortization period |
|
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
| Amortization of intangible assets |
|
|
|
|
|
|
|
|
|
|
|
$ 5,625
|
|
$ 6,250
|
|
| Common stock issued for services, shares |
|
|
|
|
|
3,750
|
|
|
|
|
|
|
|
|
|
| Patents [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research and Development Arrangement, Contract to Perform for Others, Description and Terms |
|
|
|
|
The
total cost for this license is 50,000
shares of the Company’s common stock, issuable in three tranches -
|
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of assets, shares |
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of assets, shares |
|
|
|
|
17,500
|
|
|
|
|
|
|
|
|
|
|
| Purchase of assets,value |
|
|
|
|
$ 91,000
|
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of assets, shares |
|
|
|
|
17,500
|
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of assets, shares |
|
|
|
|
16,250
|
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of assets, shares |
|
|
|
|
16,250
|
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Three [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of assets, shares |
|
|
|
|
16,250
|
|
|
|
|
|
|
|
|
|
|
| Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of assets, shares |
|
|
|
|
16,250
|
|
|
|
|
|
|
|
|
|
|
| National Institute of Health Patent License One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments for royalties |
|
|
|
|
$ 10,000
|
|
|
|
|
|
|
|
|
|
|
| National Institute of Health Patent License Two [Member] | Royalty [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty expense |
|
|
$ 8,500
|
|
|
|
|
|
|
|
|
|
|
|
|
| National Institute of Health Patent License Two [Member] | Royalty One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Intangible assets ability renew or extend arrangement |
|
|
The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time
non-refundable non-creditable royalty of $45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase
2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product.
Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is
a 3.5% of net sales royalty
|
|
|
|
|
|
|
|
The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of $45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase 2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty.
|
|
|
|
|
| Payments for royalties |
|
|
$ 45,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty expense |
|
|
$ 5,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mid-Atlantic BioTheraputics, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of assets, shares |
|
|
|
|
|
|
31,250
|
|
|
|
|
|
|
|
|
| Purchase of assets,value |
|
|
|
|
|
|
$ 1,425,000
|
|
|
|
|
|
|
|
|
| Mid-Atlantic BioTheraputics, Inc [Member] | Patents [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| License development |
|
|
|
|
6,500,000
|
|
|
|
|
|
|
|
|
|
|
| IEM, Inc [Member] | Patents [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of option |
|
|
|
|
$ 1,800
|
|
|
|
|
|
|
|
|
|
|
| Intangible assets ability renew or extend arrangement |
|
The
Company had until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM $50,000 in exchange
for an exclusive world-wide, royalty free perpetual license. In September 2021, the Company exercised the option to extend the deadline
for notification in the contract with IEM, from September 30, 2020 to March 31, 2022, in exchange for the payment of $1,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to acquire intangible assets |
|
$ 50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Intangible assets cost incurred to renew or extend, value |
$ 1,000
|
$ 1,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|